JP2025128343A5 - - Google Patents
Info
- Publication number
- JP2025128343A5 JP2025128343A5 JP2025100129A JP2025100129A JP2025128343A5 JP 2025128343 A5 JP2025128343 A5 JP 2025128343A5 JP 2025100129 A JP2025100129 A JP 2025100129A JP 2025100129 A JP2025100129 A JP 2025100129A JP 2025128343 A5 JP2025128343 A5 JP 2025128343A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- sequence number
- cdr2
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785659P | 2018-12-27 | 2018-12-27 | |
| US62/785,659 | 2018-12-27 | ||
| PCT/US2019/068820 WO2020140084A1 (en) | 2018-12-27 | 2019-12-27 | Anti-ctla-4 binding proteins and methods of use thereof |
| JP2021537082A JP7558949B2 (ja) | 2018-12-27 | 2019-12-27 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
| JP2024014900A JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014900A Division JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025128343A JP2025128343A (ja) | 2025-09-02 |
| JP2025128343A5 true JP2025128343A5 (enExample) | 2026-03-18 |
Family
ID=71126610
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537082A Active JP7558949B2 (ja) | 2018-12-27 | 2019-12-27 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
| JP2024014900A Active JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
| JP2025100129A Pending JP2025128343A (ja) | 2018-12-27 | 2025-06-16 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537082A Active JP7558949B2 (ja) | 2018-12-27 | 2019-12-27 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
| JP2024014900A Active JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12421311B2 (enExample) |
| EP (1) | EP3902821A4 (enExample) |
| JP (3) | JP7558949B2 (enExample) |
| KR (1) | KR20210121045A (enExample) |
| CN (2) | CN114008071B (enExample) |
| AU (2) | AU2019413366B2 (enExample) |
| BR (1) | BR112021012588A2 (enExample) |
| CA (1) | CA3124961C (enExample) |
| IL (2) | IL316757A (enExample) |
| MX (1) | MX2021007848A (enExample) |
| SG (1) | SG11202106764YA (enExample) |
| WO (1) | WO2020140084A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250157457A (ko) * | 2015-10-23 | 2025-11-04 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
| IL316757A (en) | 2018-12-27 | 2025-01-01 | Gigagen Inc | Anti-CTLA-4 binding proteins and methods of using them |
| AU2021299338A1 (en) * | 2020-07-02 | 2023-02-23 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| AU2021411581A1 (en) * | 2020-12-31 | 2023-07-06 | Novarock Biotherapeutics, Ltd. | Antibodies to tnfr2 and uses thereof |
| EP4362981A1 (en) * | 2021-07-02 | 2024-05-08 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| KR20240114766A (ko) * | 2021-12-10 | 2024-07-24 | 머크 샤프 앤드 돔 엘엘씨 | 인간 메소텔린 결합제 |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) * | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US20110166335A1 (en) | 2000-06-30 | 2011-07-07 | Corbin David R | Xenorhabdus sp. genome sequences and uses thereof |
| TWI320716B (en) * | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
| EP1793858A4 (en) * | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2014089113A1 (en) | 2012-12-03 | 2014-06-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| WO2015092394A1 (en) | 2013-12-17 | 2015-06-25 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| JP6449338B2 (ja) * | 2014-06-06 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用 |
| CA2976446A1 (en) | 2015-02-13 | 2016-08-18 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| SG11201708223QA (en) | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| SI3303394T1 (sl) * | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| US10618960B2 (en) | 2015-12-15 | 2020-04-14 | Oncoimmune, Inc. | Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| WO2018157147A1 (en) | 2017-02-27 | 2018-08-30 | Dragonfly Therapeutics, Inc. | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 |
| JP7173993B2 (ja) * | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| IL316757A (en) | 2018-12-27 | 2025-01-01 | Gigagen Inc | Anti-CTLA-4 binding proteins and methods of using them |
| TWI850316B (zh) | 2019-01-21 | 2024-08-01 | 法商賽諾菲公司 | 用於晚期實性瘤癌症之治療性rna及抗pd1抗體 |
| AU2021299338A1 (en) | 2020-07-02 | 2023-02-23 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
-
2019
- 2019-12-27 IL IL316757A patent/IL316757A/en unknown
- 2019-12-27 CN CN201980092796.9A patent/CN114008071B/zh active Active
- 2019-12-27 JP JP2021537082A patent/JP7558949B2/ja active Active
- 2019-12-27 SG SG11202106764YA patent/SG11202106764YA/en unknown
- 2019-12-27 AU AU2019413366A patent/AU2019413366B2/en active Active
- 2019-12-27 CN CN202510014877.4A patent/CN119930820A/zh active Pending
- 2019-12-27 BR BR112021012588-4A patent/BR112021012588A2/pt unknown
- 2019-12-27 EP EP19902920.8A patent/EP3902821A4/en active Pending
- 2019-12-27 MX MX2021007848A patent/MX2021007848A/es unknown
- 2019-12-27 CA CA3124961A patent/CA3124961C/en active Active
- 2019-12-27 US US17/418,776 patent/US12421311B2/en active Active
- 2019-12-27 WO PCT/US2019/068820 patent/WO2020140084A1/en not_active Ceased
- 2019-12-27 IL IL284156A patent/IL284156B2/en unknown
- 2019-12-27 KR KR1020217023740A patent/KR20210121045A/ko active Pending
-
2024
- 2024-02-02 JP JP2024014900A patent/JP7745669B2/ja active Active
-
2025
- 2025-06-16 JP JP2025100129A patent/JP2025128343A/ja active Pending
- 2025-08-27 AU AU2025223772A patent/AU2025223772A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025128343A5 (enExample) | ||
| JP2024042072A5 (enExample) | ||
| TWI323734B (en) | Dual variable domain immunoglobulin and uses thereof | |
| Xiong et al. | Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody | |
| JP2020504076A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP6917681B2 (ja) | 腫瘍性疾患のための治療 | |
| JP2009526856A (ja) | 抗体製剤 | |
| JP2025032102A5 (enExample) | ||
| EP3237006A1 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| KR20110031369A (ko) | 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| TW201124534A (en) | Dual variable domain immunoglobulins and uses thereof | |
| KR20110097913A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| TW201241180A (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP2011207882A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| ES2687183T3 (es) | Anticuerpos recombinantes contra el factor de crecimiento endotelial vascular (VEGF) que se obtienen mediante mutagénesis de regiones variables | |
| JP2016538297A5 (enExample) | ||
| JP2017515473A5 (enExample) | ||
| JPWO2020172605A5 (enExample) | ||
| JPWO2006046661A1 (ja) | インターロイキン−６阻害剤 | |
| JPWO2022094299A5 (enExample) | ||
| JPWO2022114163A5 (enExample) | ||
| JPWO2022067262A5 (enExample) | ||
| JPWO2022256559A5 (enExample) |